SCA
PBYI icon

SAC Capital Advisors’s Puma Biotechnology PBYI Stock Holding History

SAC Capital Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-78,938
Closed -$8.22M – 742
2014
Q1 		$8.22M Buy
78,938
+73,138
+1,261% +$8.6M 0.04% 447
2013
Q4 		$600K Sell
5,800
-10,000
-63% -$587K ﹤0.01% 1093
2013
Q3 		$848K Buy
+15,800
New +$852K ﹤0.01% 965

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SAC Capital Advisors's PBYI Position: Q2 2014 in Review

SAC Capital Advisors sold out of Puma Biotechnology (PBYI) in Q2 2014, closing a stake of 78,938 shares — an estimated $8.22M sold.

SAC Capital Advisors first reported a position in PBYI in Q3 2013 and held it in 3 quarters. The position peaked at $8.22M in Q1 2014. 137 funds tracked by Wall St. Rank hold PBYI as of Q2 2014.

  • SAC Capital Advisors reported no remaining Puma Biotechnology position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 78,938 Puma Biotechnology shares in Q2 2014, an estimated $8.22M.
  • SAC Capital Advisors first reported a position in Puma Biotechnology in Q3 2013 and held it in 3 quarters.
  • SAC Capital Advisors's Puma Biotechnology position peaked at $8.22M in Q1 2014.
  • 137 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.